Global Beta Nerve Growth Factor (Beta NGF or NGF) Drug Development Market Research Report 2022: Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.

The report outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 2, 5 and 2 respectively.

Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects.

Scope

• The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
• The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
• The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

Key Topics Covered:

Introduction

Report Coverage

• Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
• Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development

• Akeso Inc
• AstraZeneca Plc
• Chengdu Easton Biopharmaceuticals Co Ltd
• Dartsbio Pharmaceutical (Guangdong) Co Ltd
• Fujimoto Pharmaceutical Corp
• MimeTech Srl
• Regeneron Pharmaceuticals Inc
• Shandong Boan Biotechnology Co Ltd
• Staidson BioPharma Inc
• Zhuhai Trinomab Biotechnology Co Ltd

Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles

• AK-115 - Drug Profile
• Product Description
• Mechanism Of Action
• DS-002 - Drug Profile
• EP-9001A - Drug Profile
• fasinumab - Drug Profile
• Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
• MEDI-7352 - Drug Profile
• Monoclonal Antibody to Target NGF beta in Chronic Back Pain, Cancer Pain and Osteoarthritis - Drug Profile
• MT-2 - Drug Profile
• RBM-004 - Drug Profile
• Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile
• TNM-009 - Drug Profile
• TNM-010 - Drug Profile
• TNM-011 - Drug Profile
• udonitrectag - Drug Profile

History of Events

• Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
• Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
• Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones

Featured News & Press Releases

• Feb 10, 2022: Approval of clinical trial of NGF monoclonal antibody (AK115) for the treatment of pain (including cancer pain) firstly introduced by Akeso in the field of pain
• Jan 01, 2021: Congratulations to DartsBio Pharmaceutical for analgesic DS002 injection approved for clinical trial by NMPA
• Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis
• Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints
• Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis
• Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
• May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
• Dec 27, 2010: FDA Halts Development Of Regeneron's Pain Drug
• May 12, 2010: Regeneron Provides Initial Data On REGN475

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/wm8u05

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900